GRI Bio, Inc.
GRIAnalyst Consensus
Rating Trend
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Sep 10, 2026 |
| Ascendiant Capital | maintain | Buy | Aug 21, 2026 |
| Ascendiant Capital | maintain | Buy | Jun 1, 2026 |
| Ascendiant Capital | maintain | Buy | Mar 11, 2026 |
| Ascendiant Capital | maintain | Buy | Dec 8, 2025 |
| Ascendiant Capital | maintain | Buy | Sep 22, 2025 |
| HC Wainwright & Co. | maintain | Buy | Jun 11, 2025 |
| Ascendiant Capital | maintain | Buy | May 27, 2025 |
| Ascendiant Capital | maintain | Buy | Apr 21, 2025 |
| HC Wainwright & Co. | maintain | Buy | Apr 14, 2025 |
| Ascendiant Capital | maintain | Buy | Dec 5, 2024 |
Earnings History
Next report: Nov 13, 2026 · EPS est. $-0.84| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 14, 2026 | $-0.91 | $-1.19 | — | — |
| May 13, 2026 | $-1.61 | $-0.91 | — | — |
| Mar 13, 2026 | $-13.25 | $-29.27 | — | — |
| Nov 14, 2025 | $-35.85 | $-29.26 | — | — |
| Aug 14, 2025 | $-36.69 | $-36.69 | — | — |
| Aug 12, 2025 | $-162.40 | $-1.31 | — | — |
| May 15, 2025 | $-162.40 | $-105.98 | — | — |
| Nov 14, 2024 | $-319.18 | $-347.48 | — | — |
News
Chief Executive Officer Marc Hertz and Chief Scientific Officer Vipin Kumar to present on translating immune biology and clinical signals into novel therapeutic approaches for IPF
GRI Bio, Inc. (GRI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
https://www.zacks.com/stock/news/2989341/gri-bio-inc-gri-upgraded-to-buy-what-does-it-mean-for-the-stock
New whole blood RNA sequencing data identified coordinated, consistent change in genes governing immune re-balancing, myofibroblast inhibition, fibrolysis, basement membrane repair, re-epithelialization, antitussive effect and GI protection
Video webcast now available here
LA JOLLA, CA, Aug. 24, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company developing innovative therapies for inflammatory, fibrotic and autoimmune diseases, today announced that three abstracts and an oral presentation highlighting data from the Phase 2a GRI-0621-IPF-02 study have been selected for presentation at the 2026 European Respiratory Society (ERS) Congress, being held September 5-9, 2026 in Barcelona, Spain.
Bitcoin jumped 4.6% to $72,475.25 – a roughly 12% gain over the past two days after the digital asset was trading near $63,000 earlier this week.